WXIBF OTC
Credit Risk of going bust: lower than 80% of companies Debt: 1.8% of company value Bonds: none of note held by US funds details ▾
Total debt $409.3M against a stock market value of $22.80B.
Distance to default 9.56 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $67.7M (short-term plus half of long-term), stock volatility 59.7%; Altman Z'' 7.13. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Wuxi, JS 214092
CN
WuXi Biologics (Cayman) Inc. provides extensive global services, spanning the entire biopharmaceutical process from drug discovery to advanced development and manufacturing, catering to clients in China, North America, Europe, and other international markets. The company also offers expert consultation in biopharmaceutical technology, facilitates international sales contracting, develops and performs advanced testing services, and manages sales and marketing initiatives. Furthermore, it provides clinical and manufacturing support for biologics, manufactures and distributes medical products, serves as a contract development and manufacturing organization (CDMO) for vaccines, and functions as a material supplier. WuXi Biologics maintains significant strategic collaborations with partners such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc. The organization, founded in 2014, is headquartered in Wuxi, China.
-inc-logo-1200x675.png){kind=logo}